Posted by Michael Wonder on 09 May 2023
Opdivo to get reimbursement soon as primary treatment of stomach cancer
9 May 2023 - Opdivo (nivolumab), an anti-PD-1 immunotherapy, will likely receive insurance benefits soon as the primary treatment of progressive stomach cancer.
The agenda item on expanding Opdivo’s reimbursement passed the fifth drug reimbursement evaluation committee meeting under the auspices of the Health Insurance Review and Assessment Service (HIRA) last Thursday.
